Artiva Biotherapeutics, Inc. (ARTV) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
ARTV Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Artiva Biotherapeutics, Inc. (ARTV) trades at a price-to-earnings ratio of -2.4x, with a stock price of $12.52 and trailing twelve-month earnings per share of $-2.95.
Compared to the Healthcare sector median P/E of 22.3x, ARTV trades at a 111% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ARTV trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARTV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARTV P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $21B | 25.5Lowest | 6.01Best | +171%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See ARTV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARTV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARTV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARTV — Frequently Asked Questions
Quick answers to the most common questions about buying ARTV stock.
Is ARTV stock overvalued or undervalued?
ARTV current P/E: -2.4x. 5-year average P/E: N/A. Percentile: N/A.
How does ARTV's valuation compare to peers?
Artiva Biotherapeutics, Inc. P/E of -2.4x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ARTV's PEG ratio?
ARTV PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.